1801 (1801) Fair Value & Analysis
Healthcare · Market cap HK$148B
Fair value as of: Jul 2, 2026
From 23 valuation models · updated today
Share price +8.2% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$72.95 – HK$107.00 · fair‑value band HK$17.05 – HK$24.63 · the HK$85.35 price screens above the HK$21.13 fair value. As of Jul 2, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
1801 (1801) currently trades at HK$85.35, while our model-based Fair Value estimate is HK$21.13 — implying the stock looks roughly 75.2% overvalued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, 1801 generated revenue of HK$13.0B at a net margin of 6.2%. Revenue grew 29.6% year over year. It earns a return on equity of 5.0%. The balance sheet holds a net cash position of HK$14.5B. Fundamentals as of Jul 2, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
1801 reported revenue of HK$13.0B in FY2025 versus HK$4.3B in FY2021, a compound +32.2%/yr. Reported net income was HK$814M in FY2025.
Is 1801 fairly valued? → Check now
Recent news
- Eli Lilly Hands China Sales Rights for Verzenio to Innovent
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI32
- Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treat
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 1801 (1801) undervalued?
What is the fair value of 1801?
What is the quality score of 1801?
What is the revenue of 1801 (1801)?
What is the net profit margin of 1801?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.